Abstract

Case Report

Administration of G-CSF for PBSC collection may unmask pre-existing IgA-nephropathy: A case report

Florian Obereisenbuchner*, Sabine Bader-Zollner and Hans-Paul Schobel

Published: 14 September, 2022 | Volume 6 - Issue 3 | Pages: 079-082

It is utterly important to ensure the safety of stem cell donors and limit the incidence of long-term adverse events. Additionally, the willingness to donate the potentially life-saving stem cells, depends among other reasons, on the donor’s trust in the safety of the procedure as our case highlights. Here we present the case of a 35-year-old patient who developed macrohematuria and proteinuria following peripheral blood stem cell (PBSC) donation. 4 years later he was diagnosed with IgA-nephropathy (IgAN) and the disorder was causally attributed to the PBSC donation. He discouraged his family and friends from registering as donors because of this. In the current case report, we review the literature on the relationship between IgAN and PBSC donation and suggest under which conditions stem cell donation can still be performed even with a prior diagnosis of IgAN.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001094 Cite this Article Read Full Article PDF

Keywords:

IgA nephropathy; G-CSF; Hematopoietic stem cell donation; Disease exacerbation

References

  1. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009 Sep;76(5):534-45. doi: 10.1038/ki.2009.243. Epub 2009 Jul 1. PMID: 19571791.
  2. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, Gratwohl A. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009 Jan;94(1):94-101. doi: 10.3324/haematol.13668. Epub 2008 Dec 4. PMID: 19059940; PMCID: PMC2625420.
  3. Miller JP, Perry EH, Price TH, Bolan CD Jr, Karanes C, Boyd TM, Chitphakdithai P, King RJ. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):29-36. doi: 10.1016/j.bbmt.2008.05.018. PMID: 18721778.
  4. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008 Feb 15;111(4):1767-72. doi: 10.1182/blood-2007-07-097543. Epub 2007 Dec 5. PMID: 18057230.
  5. Arora S, Bhargava A, Jasnosz K, Clark B. Relapsing acute kidney injury associated with pegfilgrastim. Case Rep Nephrol Urol. 2012 Jul;2(2):165-71. doi: 10.1159/000345278. Epub 2012 Nov 21. PMID: 23326257; PMCID: PMC3542938.
  6. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, Roos D, van Oers RH, von dem Borne AE. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood. 1994 Dec 1;84(11):3885-94. PMID: 7524751.
  7. Weiss M, Moldawer LL, Schneider EM. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood. 1999 Jan 15;93(2):425-39. PMID: 9885204.
  8. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug;40(3):185-92. doi: 10.1038/sj.bmt.1705722. Epub 2007 Jun 11. PMID: 17563736.
  9. Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Freedman MH, Kannourakis G, Kinsey SE, Davis R, Scarlata D, Schwinzer B, Zeidler C, Welte K. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003 Feb;72(2):82-93. doi: 10.1002/ajh.10255. PMID: 12555210.
  10. Nasilowska-Adamska B, Perkowska-Ptasinska A, Tomaszewska A, Serwacka A, Marianska B. Acute glomerulonephritis in a donor as a side effect of allogeneic peripheral blood stem cell mobilization with granulocyte colony-stimulating factor. Int J Hematol. 2010 Dec;92(5):765-8. doi: 10.1007/s12185-010-0730-6. Epub 2010 Dec 1. PMID: 21120643.
  11. Cottle TE, Fier CJ, Donadieu J, Kinsey SE. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol. 2002 Apr;39(2):134-40. doi: 10.1053/shem.2002.31914. PMID: 11957197.
  12. Stroncek D, Shawker T, Follmann D, Leitman SF. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion. 2003 May;43(5):609-13. doi: 10.1046/j.1537-2995.2003.00384.x. PMID: 12702182.
  13. Stroncek DF, Dittmar K, Shawker T, Heatherman A, Leitman SF. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med. 2004 Jul 21;2(1):25. doi: 10.1186/1479-5876-2-25. PMID: 15268759; PMCID: PMC493285.
  14. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006 Dec;135(5):642-50. doi: 10.1111/j.1365-2141.2006.06312.x. Epub 2006 Oct 19. PMID: 17054431.
  15. Lee JB, Billen A, Lown RN, Potter MN, Craddock CF, de Lavallade H, Shaw BE, Sharpe CC. Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening. Bone Marrow Transplant. 2016 Feb;51(2):286-7. doi: 10.1038/bmt.2015.224. Epub 2015 Oct 5. PMID: 26437069.
  16. Nampoothiri RV, Kumar V, Bharati J, Lad S, Arora K, Malhotra P, Lad D. Hematopoietic stem cell donor with IgA nephropathy: Challenges and management algorithm. Transfus Apher Sci. 2020 Aug;59(4):102781. doi: 10.1016/j.transci.2020.102781. Epub 2020 May 8. PMID: 32409153.
  17. Funakoshi Y, Nazneen A, Nakashima Y, Nakashima K, Okada M, Taguchi T, Moriuchi H. Possible involvement of G-CSF in IgA nephropathy developing in an allogeneic peripheral blood SCT donor. Bone Marrow Transplant. 2010 Sep;45(9):1477-8. doi: 10.1038/bmt.2010.4. Epub 2010 Mar 1. PMID: 20190844.
  18. Billen A, Lee JBL, Lown R, Potter M, Craddock C, de Lavallade H, et al. A Proven and Probable Case of Pre-Existing IgA Nephropathy Exacerbated By Administration of G-CSF. Biology of Blood and Marrow Transplantation. 2015; 21(2):S272-S3. doi: 10.1016/j.bbmt.2014.11.432.
  19. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, Davis M, Koci B, Hammond W, Gillio A, Welte K. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol. 1994 Dec;88(4):723-30. doi: 10.1111/j.1365-2141.1994.tb05110.x. PMID: 7529539.
  20. Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, Galbusera M, Cerletti C, Barbui T. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999 Apr 15;93(8):2506-14. PMID: 10194429.
  21. Burns LJ, Logan BR, Chitphakdithai P, Miller JP, Drexler R, Spellman S, Switzer GE, Wingard JR, Anasetti C, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. Biol Blood Marrow Transplant. 2016 Jun;22(6):1108-1116. doi: 10.1016/j.bbmt.2016.02.018. Epub 2016 Mar 21. PMID: 27013014; PMCID: PMC4867293.
  22. Worel N, Buser A, Greinix HT, Hägglund H, Navarro W, Pulsipher MA, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Hölig K, Kanamori H, Kodera Y, Leitner G, Netelenbos T, Niederwieser D, van Walraven SM, Rocha V, Torosian T, Vergueiro C, Weisdorf D, Yabe H, Halter JP. Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2015 Dec;21(12):2052-2060. doi: 10.1016/j.bbmt.2015.08.009. Epub 2015 Aug 10. PMID: 26271194.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More